Preferred Label : CD133 Antigen Peptide-pulsed Autologous Dendritic Cell Vaccine;
NCIt synonyms : CD-133 Dendritic Cell Vaccine; CD133 DC Vaccine;
NCIt definition : A cell-based cancer vaccine comprised of autologous dendritic cells (DCs) pulsed with
human leukocyte antigen (HLA)-A2-restricted peptides derived from the CD133 antigen,
with potential antineoplastic activity. Upon intradermal administration, the CD133
antigen peptide-pulsed autologous DC vaccine may stimulate an anti-tumoral cytotoxic
T-lymphocyte (CTL) response against CD133-expressing tumor cells, resulting in tumor
cell lysis. CD133, a cancer stem cell marker, is expressed on hematopoietic stem and
progenitor cells and overexpressed on many types of cancer cells; it is associated
with resistance to chemotherapy and increased cancer survival. HLA-A2 is an MHC class
I molecule that presents antigenic peptides to CD8 T-cells. Epitope design that is
restricted to those epitopes that bind most efficiently to HLA-A2 may improve antigenic
peptide immunogenicity.;
NCI Metathesaurus CUI : CL471775;
Origin ID : C113794;
UMLS CUI : C3831171;
Semantic type(s)
- concept_is_in_subset
